Squamous Cell Carcinoma of the Oral Cavity Clinical Trial
Official title:
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
The advent of checkpoint inhibitors has changed the treatment landscape in SCCHN and new treatment sequences have entered clinical practice. More in-depth knowledge of tumor biomarkers are important measures for optimization of treatment strategies in SCCHN. In addition to this, investigations may involve other assessments, which will be explored separately, such as molecular testing. These tests are then linked to the core data set and will allow to associate such measures with outcomes. This concept is flexible and allows for rapid integration of contemporary research questions in a timely manner. Furthermore, insights into the treatment reality for recurrent/metastatic salivary gland carcinoma and other rare tumor entities (SNUC, etc.) are urgently needed, as there is currently no established standard of care. The monoclonal antibody cetuximab in combination with platinum and fluorouracil (EXTREME) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade.1 Recently, the immune checkpoint inhibitors (CPIs) nivolumab and pembrolizumab have changed the therapeutic landscape of patients with r/m SCCHN. Nivolumab is considered as therapeutic standard after failure of platinum-based therapy based on the results of the phase III Checkmate-141 trial.2 In addition, pembrolizumab has become the new standard in the first-line setting in combination with platinum/fluorouracil chemotherapy or as monotherapy for patients with programmed cell death ligand 1 (PD-L1) positive tumors based on the data from the phase III Keynote-048 trial.3 Moreover, cetuximab in combination with platinum and docetaxel (TPEx) has emerged as a less toxic alternative to the EXTREME regimen.4 Due to the shifting first-line treatment landscape, data to guide contemporary 2nd line therapy are scarce and the optimal treatment sequence remains vague.2,5,6 The implementation of biomarkers and selection of patients in a real-world setting are areas of academic interest. In addition, the assessment of treatment outcomes in rare entities are underrepresented in pivotal trials, and as a matter of fact, may be completely excluded. However, broad labels permit the use of novel agents, but a larger body of evidence is needed to substantiate such treatment choices. HEAT seeks to address these questions by inclusion of a real-world patient population and continuous assessment of oncological outcomes by means of a core clinical data set implemented into HEAT. Overall, HEAT is a study platform, which continuously assesses clinical outcomes and modularly integrates additional measures to enable rapid answers to research questions. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540899 -
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT01108042 -
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03721757 -
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
|
Phase 2 | |
Completed |
NCT02873819 -
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
Active, not recruiting |
NCT04387682 -
Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients
|
N/A | |
Completed |
NCT01321892 -
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
|
N/A | |
Completed |
NCT01636544 -
Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity
|
N/A | |
Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
Withdrawn |
NCT04831450 -
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
Recruiting |
NCT04191460 -
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
|
Phase 2 | |
Recruiting |
NCT06030440 -
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2/Phase 3 | |
Terminated |
NCT01077869 -
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
|
Phase 1 | |
Completed |
NCT02609386 -
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
|
Phase 2 | |
Not yet recruiting |
NCT05452408 -
Antitumor-B KAC PK Study
|
Phase 1 | |
Not yet recruiting |
NCT03364166 -
Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma
|
N/A | |
Terminated |
NCT02331875 -
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
|
Phase 1/Phase 2 | |
Completed |
NCT01265849 -
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
|
Phase 3 | |
Active, not recruiting |
NCT03370276 -
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT03575598 -
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
|
Early Phase 1 | |
Active, not recruiting |
NCT03459729 -
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
|
Early Phase 1 |